The discovery that TSC1 or TSC2 mutations cause dysregulation of mTORC1/mTORC2 led to preclinical studies (20–25) and human clinical trials demonstrating therapeutic efficacy of mTORC1 inhibitors (mTORi) in TSC and LAM (26–31). This evidence concerns the gene TSC1 and lymphangioleiomyomatosis.